






# MRI of peritoneal diseases

Vincent Vandecaveye,
Department of Radiology, University Hospitals
Leuven, Leuven/BE

## Peritoneal tumour: primitive versus secondary

Secondary peritoneal tumours much more frequent then primary



## Computed Tomography: Difficult to predict peritoneal resectability or lymph node involvement

## Insufficient accuracy to predict (in)complete resection


	Sensitivity	Specificity	PPV	NPV	Pre-test probability	Post-test probability
1. Ferrandina model A: cut-	-off > 5/8					
Ferrandina et al.	22,9	97.7	92.6	50.0	55.8	92.6
Reader 1	23,2	88.0	68.4	50.6	53.6	68.4
Reader 2	34.0	84.3	69.2	55.1	53.6	69,2
Reader 3	31,3	86.1	75.0	48.4	53.6	75.0
2. Ferrandina model B: cut-	off > 3/5					
Ferrandina et al.	23.9	97.7	92.8	50.3	55.8	92.8
Reader 1	18,2	92,0	71.4	50.5	53.6	71.4
Reader 2	32,3	88.5	76.9	52.3	53.6	76.9
Reader 3	31,3	85.7	75.0	47.6	53.6	75.0

Rutten IJ et al, Gynecol Oncol 2016



<sup>\*\*</sup> Lower sensitivity for liver metastases in case of steatosis (31-38%)

- \*\* Lymph nodes < 1 cm difficult to stage Threshold nodal N+ chest = 0,5 cm!
- \*\* Small or less conspicuos peritoneal metastases: Intestinal serosa: 21-25% sensitivity Peritoneal metastases < 5 mm: 11% sensitivity







Diffuse carcinomatosis


Modality	Sensitivity	Specificity	Diagnostic OR
Region based	1		
CT	0.68 (0.46-0.84)	0.88 (0.81-0.93)	15.9 (4.38–58.01)
PET(CT)	0.79 (0.092)	0.90 (0.80-0.96)	36.5 (6.7–200.0)
(DW)MRI	0.91 (0.96)	0.85 (0.78-0.91)	63.3 (31.5–127.3)
Patient based			
CT	0.70 (0.53-0.83)	0.94 (0.87–0.97)	33.5 (16.3–69.0)

Data in parentheses are 95% confidence interval, OR odds ratio

van 't Sant I et al, Eur Radiol 2020













Helsinki museum of art

# Rationale for (WB-)DWI/MRI

	PET/CT				MR-DWI				p
	Se	Sp	PPV	NPV	Se	Sp	PPV	NPV	
Sites									
Right supramesocolic	60 (3/5)	92 (23/25)	60 (3/5)	92 (23/25)	100 (5/5)	100 (25/25)	100 (5/5)	100 (25/25)	0.48
Left supramesocolic	25 (1/4)	96 (25/26)	50 (1/2)	89 (25/28)	50 (2/4)	100 (26/26)	100 (2/2)	93 (26/28)	1
Inframesocolic	72 (13/18)	75 (9/12)	81 (13/16)	64 (9/14)	72 (13/18)	83 (10/12)	87 (13/15)	67 (10/15)	0.08
Total	63 (17/27)	90 (57/63)	74 (17/23)	85 (57/67)	74 (20/27)	97 (61/63)	91 (20/22)	90 (61/68)	0.27
Interobserver agreement $(\kappa)$	0.92 (0.71,	1.12)			0.78 (0.57-	0.99)			

#### Soussan M Eur Radiol 2012






Not affected by underlying anatomy or metabolism


DWI improves site based lesion detection


detection of surgically critical disease site


## Short Tau inversion recovery (STIR) DWI/MRI












+ chest CT + PET/CT


\* 3 hours fasting (reduces small bowel motility)


- \* Negative peroral contrast :
- pineapple juice 7% barium/1 Liter water
- \* Antispasmodic

#### Frequency-based fat-saturation DWI (SPAIR, SPIR,....)

#### Short Tau Inversion Recovery (STIR) DWI








## Image interpretation: sequence selection

DWI = core sequence


- Detection
- Characterization

B-value: 1 low (0-50) and 1 high (b1000)

ADC minor to no role for staging



Whole Abdomen (+ chest CT orPET/CT)





- → Qualitative assessment: peritoneal implant = B1000 intensity not attributable to T2 shine-through
- bowel wall signal (pine apple/antispasmodic) or artifact (STIR)


## Image interpretation: sequence selection


DWI's best friend



Coronal
T2 single shot
3 stacks (whole body)
48 cm z axis
Free breathing
6 mm
Stitch

Transverse
T2 single shot 2 stacks
48 cm z axis
Abdomen -trigger
Pelvic - free breathing
6 mm
Stitch





- \* Anatomical correlation
- \* Exclude T2 shine-through
- \* Characterize mucinous tumour
- \* Detect Non DWI-avid lesions

Fully replaces contrast imaging when contra-indication

## Image interpretation: sequence selection


The surgeon's best fri<mark>end</mark>


Post-Gadolinium T1 gradient-echo 3-5 minutes post-injection


Breath-hold Pelvis/abdomen: transverse/Coronal

Chest: transverse


3 mm















Signet cell cancer



- \* Anatomical correlation
- \* Lesion detection < 4 mm
- = spatial resolution limit of DWI
- \* Non DWI-avid lesions

## Image interpretation: b1000 + anatomical correlation



Nodular pattern

Confluent pattern

miliary pattern


infiltrative pattern


High grade ovarian – colorectal cancer

Lobular, low grade ovarian – gastric pancreatic cancer

## Lymph nodes - lymphadenopathies

- Extra benefit of STIR = T1 based prepulse:
- Malignant lesions have a higher T1 than benign + better suppression of benign tissue
- Facilitates qualitative interpretation of lymph nodes





N+: SI ≥ primary tumor N- : SI < than primary tumor



N+: SI SI  $\geq$  primary tumor surrounding lymph nodes N-: SI  $\approx$  surrounding lymph nodes



Rizzo S et al. Eur J Radiol 2020


Re	etroperitoneum	TP	FN	FP	TN	Sens	Spec	PPV	NPV	Acc
	WB-DWI/MRI	10	3	3	29	0.77	0.91	0.77	0.91	0.87
	ст	7	6	7	25	0.54	0.78	0.50	0.81	0.71
	FDG-PET/CT	10	3	3	29	0.77	0.91	0.77	0.91	0.87

ovarian cancer 161 patients (Michielsen et al; Eur J Cancer 2017)

#### Table 2 Weighted summary of sensitivity, specificity, and OR for eac

	Sensitivity	Specificity
WB-DWI		
Pooled estimates	0.897	0.954
95%CI P value* I <sup>2</sup> value	0.876-0.916 P-0.000 85.60%	0.944-0.962 P-0.000 91.40%
WB-PET/CT		
Pooled estimates	0.895	0.975
95%CI	0.865-0.920	0.900-0.981
P value*	P = 0.000	P-0.000
I <sup>2</sup> value	90.40%	83.40%

#### Bin L et al, Eur J Radiol



## Image interpretation: Distant metastases/lymphadenopathies

#### <u>lung metastases?</u>

+ Equal performance as CTPer patient basis- Lower performancePer-lesion basis

#### ORIGINAL ARTICL

Detection Rate, Location, and Size of Pulmonary Nodules in Trimodality PET/CT-MR

Comparison of Low-Dose CT and Dixon-Based MR Imaging


Paul Stolzmann, MD, Patrick Veit-Haibach, MD, Natalie Chuck, MD, Cristina Rossi, PhD, Thomas Frauenfelder, MD, Hatem Alkadhi, MD, MPH, Gustav von Schulthess, MD, PhD, MD(Hon), and Andreas Ross, MD, PhD


#### No. and Size (mm) of Nodules


Low-dose CT	wo M	RI IP
n = 66	n = 56	n = 58
19 (19; 2–69)	18 (18; 2–64)	17 (17; 2–67)
n = 36	n = 33	n = 35
32 (18; 3–69)	28 (16; 6–64)	28 (16; 5–67)
n = 30	n = 23	n = 23
5 (5; 2–30)	6 (10; 2–50)	5 (4; 2–24)

#### Patient-Based Detection Rates (n = 40)


		, ,
Low-dose CT 34/40; 85%	WO M 33/40; 83%.	P IP 33/40; 83%
26/40; 65%	25/40; 63%	25/40; 63%
18/40; 45%	18/40; 45%	18/40; 45%




















## 1/ Confirm primary origin





**Fig. 36** Differential diagnosis of peritoneal malignancies based on imaging findings. MPM = Malignant Peritoneal Mesothelioma, PPSC = Primary Peritoneal Serous Carcinoma, LAMN = Low-Grade Appendiceal Mucinous Neoplasm, HAMN = High-Grade Appendiceal Mucinous Neoplasm, BMM = Benign Multicystic Mesothelioma, NET = Neuroendocrine Tumor, DSRCT = Desmoplastic Small Round Cell Tu

- DDx of primary from metastatic peritoneal tumours is non-straightforward
- Histopathology after core biopsies requiered for final diagnosis  $\rightarrow$  obliged in neoadjuvant chemotherapy
- Knwoledge of radiological features that can guide initial diagnosis → impact management

## 1/ Confirm primary origin: malignant mesothelioma

Patient 41 years old, over years periods of acute abdomen, relieved with corticoids/NSAID





Mesenteritis? - IgG4 inflammatory disease?

#### MRI:


- \*Operability? → predicts incomplete resection
- \*Primary tumour? → none found

#### Laparoscopy:


- \*Operability predicts complete resection
- \* Histopathology after biopsy: malignant mesothelioma

Incomplete debulking surgery followed by atezolizumab

Best treatment appears corticoids/NSAID in 2024









## 1/ Confirm primary origin: malignant mesothelioma


## Clinical context:

Men 60% – Women 23% asbestosis exposure – 30% simultaenous pleural involvement Men (median 60 years) > women (median 50 years)
Occasionally seen in young patients without exposure history
Non-specific abdominal dyscomfort, pain, local palpable mass



Sarcomatoid type: solid masses "sarcomatoid" appearance








Epitheloid type: infiltrative, small nodules, multifocal "carcinomatosis" appearance

Imaging appearance does not strictly predict histological tumor type (mixed types

## 1/ Confirm primary origin: malignant mesothelioma







Main imaging feature:

Contrast-enhancement at CT and MRI: conspicuous at both modalities

Cystic component due to mucinous component or degeneration

DWI b1000 +++ in the tumoral component,

Absent DWI b1000 allows distinction of inflammatory component

## Differential diagnosis > histopathological diagnosis

#### As opposed to:

- Peritoneal metastases
- Infections like tuberculosis


#### Consider when:


Absence of primary tumour; lymphadenopathies and visceral metastases Sheetlike thickening of peritoneum or sarcomatosis-like appearance Signs of asbestosis exposure


#### As opposed to:

- Well-differentiated mesothelioma
- Multicystic mesothelioma (uncertain malignant potential)

No diffusion restriction
Simple cystic nature
No ehancement










## 1/ Confirm primary origin: Primary peritoneal papillary serous carcinoma

60 year old patient with bloating and vaginal bleeding.




Peritoneale calcifications









WB-DWI/MRI for staging operability

No identifyable primary tumour Normal ovaries

Upfront debulking surgery to R0: Primary peritoneal papillary serous carcinoma

## 1/ Confirm primary origin: Primary peritoneal papillary serous carcinoma

Women aged between 50 and 60 years old.

Complaints of abdominal distention, pain, bloating, nausea and vomiting. Increase of CA-125

Histologically, immunohistochemically identical to metastatic serous ovarian carcinoma implants, but arises from extra-ovarian mesothelium with Mullerian potential


Treatment identical to ovarian cancer.


Imaging appearance overlaps with (low grade) ovarian cancer  $\rightarrow$  no identifiable tumour at the ovaries. Overall, mimic peritoneal metastases of ovarian cancer.


Key imaging feature: psammomatous calcifications (up to 30% of patients) and absence of ovarian mass.

→ Potential pitfall for MRI staging, calcified lesions less apparent.









## 1/ Uncertain origin: Desmoplastic small round cell tumour


Men < 30 years (mean 19 years)
Non-specific abdominal complaints
Extremely rare

- Main imaging features:
- Diffuse peritoneal spread
- Dominant intraperitoneal tumour > 10 cm\*
- with intratumoral necrosis
- Punctate calcifications in the tumoral masses
- Commonly lymph node and visceral metastases

Differential diagnosis

Lymphomatosis > carcinomatosis











## 1/ Uncertain origin: disseminated peritoneal leiomyomatosis


Smooth muscle nodules and masses in the peritoneal cavity.


Metaplasia of submesothelial smooth muscle


Risk factors: uterine leiomyoma, high oestrogen levels


prior hysterectomy or myomectomy


myoma morcellation











Key imaging feature: T2, contrast-MRI and DWI behave like myometrium – increased ADC Differential diagnosis: Sarcomatosis, sarcomatoid mesothelioma

## 1/ Confirm primary ovarian malignancy ( $\leftarrow \rightarrow$ ) exclude other cancer mimicking ovarian cancer

- → Key process in initial treatment selection: primary ovarian, colon, pancreatic, gastric cancer, NET...
- $\rightarrow$  B1000 + anatomy
- → Often in the context of malignant ovarian mass ± peritoneal metastases

Primary tumour identification in peritoneal carcinomatosis

Direct idenfication of Primary tumour

Radiological appearance
Peritoneal metastases
Carcinomatosis
Pseudomyxoma?
Sarcomatosis?
Lymphmatosis?
Neuroendocrine?

Atypical distribution of distant metastases: Liver, Bone, lung  $\rightarrow$  Search for other primary than ovarian

# Fused b1000/DWI


Ovarian cancer Incidental breast cancer

## Primary tumor ID: if ovarian mass


\*\* WB-DWI : 81% accuracy
\*\* CT : 31% accuracy


Michielsen K et al, EJC 2017





# Direct idenfication of primary





Nodular pattern

Confluent pattern

Infiltrative/miliary pattern

Signet ring cell patterr

Peritoneal carcinomatosis: Ovary, Gl adenocarcinoma, **Gastric cancer**, Pancreas, lobular breast cancer Pattern not tumour specific but often detectable primary tumour (previous slide).

Pseudomyxoma peritonei:

Appendix: LAMN/HAMN 🖊

Colon/rectum: mucinous - worse prognosis


Ovary: mucinous - (rare) – Bad prognosis


#### Radiological features:


- Loculated ascites
- T2 -ADC halo at fluid/tissue interface
- Scalloping of solid organs /
- Solid and Cyst-like implantes with internal septae.

MRI > CT for detection mucinous implants


Main differential: Malignant mesothelioma (Mucinous degeneration)











#### Peritoneal sarcomatosis:

Heterogeneous group of tumours.

GIST: most frequent

Leimyosarcoma

Liposarcoma (dedifferentiated and myxoid type)

Myxoid (lipo)sarcomas (even extremity although rare)

Key radiological features that allow differentiation:


- Bulky solid masses /
- Hyperenhancement and DWI +++
- Fat content (liposarcoma)
- Myxoid appearance (Myxoid sarcoma)
- → MRI > CT to characteriza and stage lesions


Detection more important than staging for operability assessment (exception for GIST.

Presence of peritoneal sarcomatosis = upfront inoperability


Main differential: sarcomatoid varian of mesothelioma








## Peritoneal sarcomatosis: Liposarcoma




Man 52 years. Intraperitoneal recurrence Liposarcoma CT and MRI: Lipid content, thin walled



Man 41, years old, curative resection of Myxoid Liposarcoma of the knee








Man, 23 years, night sweats, abdominal pain, obstruction

Peritoneal lymphomatosis:
Mostly non-Hodkin large B-cell lymphoma.

Radiological peritoneal findings can be non-specific and overlap with peritoneal carcinomatosis. Mildly enhancing bulky masses, wall thickening of long segments of small bowel loops. Search for typical patterns of lymphadenopathies. PET/CT imaging standard.


## Diagnosis primary origin – operability – disease stage



2/ Distant metastases (Non-)Resectability?

Resectability distant metastases? and lymph nodes (1)
Pleural metastases (2)
Suprarenal lymph nodes (3)

Liver, lungs, skeletal




3/ Peritoneal metastases (Non-) Resectability?


Surgically critical disease sites
Peritonal cancer index

4/ Complications
Hydro-ureteronefrosis
Thrombosis


• • • •


# From Peritoneal anatomy....








# From Peritoneal anatomy...















# To surgically critical peritoneal anatomy.....

×



#### Regions Lesion Size

- o central
- 1 Right upper \_\_\_\_\_
- 2 Epigastrium
- 3 Left upper \_\_\_\_\_
- 3 Lett upper
- 4 Left flank
- 5 Left lower \_\_\_\_\_
- 6 Pelvis
- 7 Right lower
- 8 Right flank
- 9 Upper jejunum \_\_\_\_\_
- 10 Lower jejunum \_\_\_\_\_
- 11 Upper ileum
- 12 Lower ileum \_\_\_\_\_

PCI 0-39




LS o No tumor seen

LS 1 ≤ 0.5 cm

LS 2 > 0.5 cm to ≤ 5.0 cm


LS 3 > 5 cm or confluence





PCI > 15 threshold → surival

1/Peritoneal Cancer Index



# To surgically critical peritoneal anatomy.....

## 2/standardized predictive score

#### Espada M et al, Eur Radiol 2013

Table 1 Fledictive accuracy of Dwiving for affection of anatomical sites in EL	Table 1	Predictive accuracy	of DWMRI f	for affection o	f anatomical sites in EL
--	---------	---------------------	------------	-----------------	--------------------------

Anatomic feature		Sensitivity	Specificity
Involvement of small and/or la	rge bowel mesentery	100 % (8/8)	84.6 %(22/26)
Involvement of hepatic parenc or surface implant >2 cm	hyma, hepatic hylium	80.0 % (8/10)	83.3 % (20/24)
Involvement of spleen parench stomach or lesser sac	yma, spleen hylium,	100 % (11/11)	100 % (23/23)
Involvement of diaphragm		80.0 % (4/5)	96.6 % (28/29)
Peritoneal thickening		69.2 % (9/13)	81.0 % (17/21)
Peritoneal macroscopic implan	ts (≥2 cm)	69.2 % (9/13)	81.0 % (17/21)
Massive ascites		50.0 % (4/8)	92.0 % (23/25)
Suprarenal para-aortic lymph i	nodes (≥1 cm)	100 % (5/5)	86.2 % (25/29)
Miliar visceral peritoneum imp	olants	91.7 % (11/12)	95.5 % (21/22)
Involvement of pelvic sidewal	and/or hydroureter	100 % (1/1)	93.9 % (31/33)

	Essen criteria	Leuven criteria	
	Biopsy with histologically proven epithelial ovarian (or tul	bal or peritoneal) cancer FIGO stage IIIC-IV	
	-	Or fine needle aspiration proving the presence of carcinoma cells in patients with a suspicious pelvic mass if CA125 (KU/L)/CEA (ng/mL)	
П		ratio is > 25. If the serum CA125/CEA ratio is ≤ 25, imaging or endoscopy	
		is obligatory to exclude a primary gastric, colon or breast carcinoma	
П	Involvement of the superior mesenteric artery		
П	Diffuse deep infiltration of the radix mesenterii of the small	l bowel	
	Diffuse and confluent carcinomatosis of the stomach and/o short bowel syndrome or a total gastrectomy	or small bowel involving such large parts that resection would lead to a	
	Multiple parenchymatous liver metastases in both lobes	Intrahepatic metastases	
П	Tumor involving large parts of the pancreas (not only tail)	Infiltration of the duodenum and/or pancreas and/or the large vessels of	
П	and/or the duodenum	the ligamentum hepatoduodenale, truncus coeliacus or behind the porta	
П	Tumor infiltrating the vessels of the lig. Hepatoduodenale	hepatis	a
	or truncus coeliacus		
	Not completely resectable metastases, as eg.	All excluding:	
П	- Multiple parenchymal lung metastases (preferably	- Resectable inguinal lymph nodes	a
П	histologically proven)	- Solitary resectable retrocrual or paracardial nodes	
	- Non resectable lymphnode metastases	- Pleural fluid containing cytologically malignant cells	
	- Brain metastases	without proof of the presence of pleural tumors	



Vergote I, et al. Gynecol Oncol. 2013;128(1):6-11.

#### Table 3 Predictive parameters upon the score threshold selected NPV Specificity PPV Total score Sensitivity Accuracy Unnecessarily Inappropriately explored (%)a points unexplored (%)b DWMRI 100 % (8/8) 34.6 % (9/26) 32.0 % (8/25) 100 % (9/9) ≥1 50 % (17/34) 0 % 65.4 % (17/26) ≥2 100 % (8/8) 61.5 % (16/26) 44.4 % (8/18) 100 % (16/16) 70.5 % (24/34) 0 % 38.5 % (10/26) >3 100 % (8/8) 69.2 % (18/26) 50.0 % (8/16) 100 % (18/18) 76.4 % (26/34) 30.8 % (8/26) 58.3 % (7/12) 82.3 % (28/34) 12.5 % (1/8) 19.2 % (5/26) ≥4 87.5 % (7/8) 80.8 % (21/26) 95.5 % (21/22) ≥5 75.0 % (6/8) 92.3 % (24/26) 75.0 % (6/8) 92.3 % (24/26) 88.2 % (30/34) 25.0 % (2/8) 7.7 % (2/26) ≥6 25.0 % (2/8) 3.8 % (1/26) 75.0 % (6/8) 96.2 % (25/26) 85.7 % (6/7) 92.6 % (25/27) 91.1 % (31/34) 62.5 % (5/8) 96.2 % (25/26) 83.3 % (5/6) 89.3 % (25/28) 88.2 % (30/34) 37.5 % (3/8) 3.8 % (1/26) ≥8 12.5 % (1/8) 100 % (26/26) 100 % (1/1) 78.8 % (26/33) 79.4 % (27/34) 87.5 % (7/8) 0 % (0/26)

3/Site based predictive score

## 2/ Distant metastases/lymphadenopathies in ovarian cancer (Stage IVA and IVB - (Non-)Resectability?

#### Resectable metastases


- Inguinal, axillary N+
- Solitary retrocrural or paracardiac N+
- Cytology + pleural fluid without deposits

#### Irresectable metastases


- Multifocal lung- or liver M+
- Brain metastases
- Irresectable N+:
  - Mediastinum
  - Internal mammary chain
  - Neck
  - Retroperitoneum above renal vein

Resectable – upfront or after NACT Depending on abdominal disease


Pleural metastases lower 1/3 chest







Stage IVB irresectable




Stage IVB resectable

Rizzo S et al, Eur J Radiol 2020


## 3/ Peritoneal metastases: (Non-)Resectability?








\*\* Upper abdomen







WB-DWI/MRI	15	1	77	1	93.8 [71.7-98.9]	98.7 [93.1-99.8]	93.8 [71.7-98.9]	98.7 [93.1-99.8]	97.9 [92.6-99.4]
ст	11	1	77	5	68.8 [44.4-85.8]	98.7 [93.1-99.8]	91.7 [64.6-98.5]	93.9 [86.5-97.4]	93.6 [86.8-97.0]

#### Michielsen K et al, EJC 2017



Rizzo S et al, Eur J Radiol 2020

Involvement of hepatic parenchyma, hepatic hylium 80.0 % (8/10) 83.3 % (20/24) 66.6 % (8/12) 90.9 % (20/22) or surface implant >2 cm

Espada M et al, Eur Radiol 2013

Rizzo S et al, Eur J Radiol 2020

Pericardiophrenic lymph nodes 28 10 1 15 28 6 3 13 89.3 (71.8-97.7) 67.9 (47.6-84.1)

0.01

## 3/ Peritoneal metastases: (Non-)Resectability?

Eur Radiol (2014) 24:889-901 DOI 10.1007/s00330-013-3083-8


UROGENITAL


Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT


Katrijn Michielsen • Ignace Vergote • Katya Op de beeck • Frederic Amant • Karin Leunen · Philippe Moerman · Christophe Deroose · Geert Souverijns · Steven Dymarkowski · Frederik De Keyzer · Vincent Vandecaveye


## Intestinal deposits






















Bowel serosal and me	senteri	al invo	lveme	Specificity	Sensitivity	Асситасу	
Our study US	34	18	2	13	0.94	0.42	0.70
			_		(0.81-0.99)	(0.25-0.61)	(0.58-0.81)
WB-DWI/MRI	32	11	4	20	0.89	0.65	0.78
OT	22		2	20	(0.74=0.97)	(0.45=0.81)	(0.66–0.87) 0.79
CT	33	11	5	20	0.92 (0.78=0.98)	0.65 (0.45=0.81)	(0.67-0.88)
					(0.78-0.98)	(0.45-0.81)	(0.67-0.88)

Fischerova D et al, Ultrasound Obstet Gynecol. 2022

## Predicting R0 surgery in primary diagnosis of ovarian cancer: MRI >>>>CT



Espada M et al, Eur Radiol 2013

standardized predictive score

Table 4
Comparative accuracy for predicting incomplete resection.

Diagnostic accuracy	WB-DWI	CT
TP	47	33
FP	1	10
TN	43	34
FN	3	17
Sensitivity <sup>a</sup>	<b>94.0</b> (84–98)	<b>66.0</b> (52–78)
Specificity <sup>a</sup>	<b>97.7</b> (88–100)	<b>77.3</b> (63–87)
Positive predictive value <sup>a</sup>	<b>97.9</b> (89–100)	<b>76.7</b> (62–87)
Negative predictive value <sup>a</sup>	<b>93.5</b> (83–98)	<b>66.7</b> (53–78)
Accuracy <sup>a</sup>	<b>95.7</b> (90–98)	<b>71.3</b> (61-79)

WB-DWI, whole body diffusion-weighted imaging; CT, computed tomography; TP, true positive; FP, false positive; TN, true negative; FN, false negative.


a Numbers indicate percentages (95% confidence interval based on Wilcon Score).


Michielsen K et al, EJC 2017


Site based interpretation

Prediction of (in)complete resection → operability assessment

## WB-DWI/MRI in primary ovarian cancer staging and operability assessment








New diagnosis of ovarian cancer: PET/CT limited disease load – WB-DWI/MRI diffuse invasive miliary M+ (IIIC)


## WB-DWI/MRI in primary ovarian cancer staging and operability assessment



CT-scan: Retroperitoneal adenopathy

→ MRI peritoneal staging prior to secundairy debulking surgery





# MRI - Diseases of the peritoneum – take home messages

\* Metastatic peritoneal tumours most common – consider also primary diseases

- \* MRI sequence protocol is basic but should cover large volume:
- STIR-DWI > SPAIR DWI for whole body or full abdomen MRI
- T2, DWI (b50-1000) and 3-5 minutes delayed contrast-MRI (Transverse and coronal)
- \* MRI protocol takes 38 minutes or less, more complicated interpretation, high precision in small lesion detection:
- → Operability assessment

MRI anatomy should match surgical anatomy to standardize communication with referring clinician

- \*\* Surgically critical tumour sites
- \*\* Peritoneal Cancer Index